Biomarkers Predicting Atrial High Rate Episodes in Cardiac Implantable Electronic Device Recipients
Predictors of Atrial High Rate Episodes in Patients Implanting Cardiac Implantable Electronic Device Based on Biomarkers
1 other identifier
observational
100
1 country
1
Brief Summary
This study is sought to investigate any predictors including biomarkers for atrial high rate episodes (AHRE) occurrence in patients without prior history of atrial tachyarrhythmias receiving cardiac implantable electronic device (CIED).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 24, 2022
CompletedStudy Start
First participant enrolled
July 24, 2022
CompletedFirst Posted
Study publicly available on registry
July 27, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2024
CompletedJuly 27, 2022
July 1, 2022
1.6 years
July 24, 2022
July 24, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
The occurrence of atrial high rate episode
12 months
Secondary Outcomes (1)
Factors predicting the occurrence of atrial high rate episode
12 months
Study Arms (1)
Patients receiving cardiac implantable electronic device
Patients receiving cardiac implantable electronic device for any clinical indication
Interventions
implantable cardiac electronic device recipients for any clinical indication
Eligibility Criteria
Patients receiving cardiac implantable electronic device for any clinical indication (pacemaker, implantable cardioverter-defibrillator, cardiac resynchronization therapy)
You may qualify if:
- patients receiving cardiac implantable electronic device
You may not qualify if:
- patients who disagree for blood sampling to analyze not commonly used clinical biomarkers
- patients not followed-up at least 12 months after implanting device
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Jinhee Ahn
Busan, South Korea
Biospecimen
biomarkers including soluble ST-2 and FGF-23, single nucleotide polymorphism
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jinhee Ahn, MD
Clinical associate professor
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical associate professor
Study Record Dates
First Submitted
July 24, 2022
First Posted
July 27, 2022
Study Start
July 24, 2022
Primary Completion
February 28, 2024
Study Completion
July 31, 2024
Last Updated
July 27, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share